about
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyRisk for myasthenia gravis maps to a (151) Pro→Ala change in TNIP1 and to human leukocyte antigen-B*08Afferent Visual Pathway Affection in Patients with PMP22 Deletion-Related Hereditary Neuropathy with Liability to Pressure Palsies.MK2 and Fas receptor contribute to the severity of CNS demyelination.Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.Measuring Compounds in Exhaled Air to Detect Alzheimer's Disease and Parkinson's Disease.Increased Frequency of T Follicular Helper Cells and Elevated Interleukin-27 Plasma Levels in Patients with Pemphigus.Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab.Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.Neurofascin as a target for autoantibodies in peripheral neuropathies.Novel multiple sclerosis susceptibility loci implicated in epigenetic regulationImpaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.The immunopathogenesis of myasthenia gravis.Terminal complement activation is increased and associated with disease severity in CIDPPreference-based Health status in a German outpatient cohort with multiple sclerosis.Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).Cytokines and epilepsy.Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.Whole-body vibration therapy in intensive care patients: A feasibility and safety study.Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array.IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis.Economic burden in a German cohort of patients with multiple sclerosis.Anti-JC-virus antibody prevalence in a German MS cohort.Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy.Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy.Akinetic crisis caused by rectus sheath hematoma and acute anemia due to subcutaneous administration of apomorphine.Serum titers of autoantibodies against α-synuclein and tau in child- and adulthood.Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management.Nigrostriatal dysfunction in X-linked dystonia-parkinsonism (DYT3).
P50
Q26765172-E9FECD83-3B40-46BA-99CE-7BECEF7B5F64Q28943379-6342D5C7-463C-45B8-B276-C4AB269ADC0DQ30371672-905350C2-08AE-4534-9AA7-A94481370C49Q33806619-E73DC65F-420D-48E5-A304-BA189104B852Q34538700-8A635EB8-BD1E-4D37-9E56-3EAD5BA1EB48Q34618619-024A5A6E-5860-42BD-95B5-A60856FC544CQ35846547-92400E76-CBE3-43D6-902F-772F3BFBC379Q35922554-852FC21F-E612-428B-9D5F-D1679E23AD2CQ36073992-6D279208-537E-4E5F-B398-F4DB50B7984AQ36266469-CC678357-8A99-417B-B6C4-C6F6A25B57B1Q36524437-09153EDE-C216-4EFE-B221-603387F319A3Q37056269-17C7DB34-8A3F-453C-BFE9-8213B9C21BF8Q37140095-534FB6C8-95CB-4CD1-86A1-EB421A3C2B89Q37218062-50C13609-B633-4186-90C0-6F91AEB1555DQ37247076-85FD88D6-9464-4E96-B490-8D40727DBF39Q37364780-B49D7DFA-8C8C-4A94-AFDC-FE41828FA276Q37542243-882E848C-DE77-4E84-AB56-3694046AD363Q37826990-2893ED11-EBBB-4108-82CD-506C88B5F764Q39214015-1C5A3C4F-CFF9-439F-9133-428441132C78Q40067105-0181D628-90A2-4CDD-B181-EE89CD1AD4E1Q41189386-D294F8B2-928E-4300-9BDB-53F567509EC7Q42136819-3910BD7C-357B-45D3-8025-95CCC29ACDDFQ43578595-B90A59B4-B00F-453B-8D7A-DE1B20C873E7Q44228231-8E8D82D2-0488-4DB4-A734-E7CF49062663Q44545095-7B3FD2D1-56E5-4CDC-A939-C982C8624761Q44840261-70A5D8B4-9D4E-44A0-9205-0E08934C9055Q44938493-40549EE3-4FD7-4BC2-994F-84AC07640458Q46665324-CCFD851C-8E63-46A8-938B-5366B8583825Q46701951-77F889B1-BACE-4724-B64F-FC6D213CF71DQ47227567-4043C024-FF19-41C9-928F-BCFFAB95288CQ47255582-41E82A8F-B659-41F2-A444-A984A5C8FEC7Q47550502-E459C487-7C59-4C78-808B-61251683121BQ48232317-0DABB0DC-AA90-4554-AB47-F1A205B48B07
P50
name
Björn Tackenberg
@ast
Björn Tackenberg
@en
Björn Tackenberg
@es
Björn Tackenberg
@nl
type
label
Björn Tackenberg
@ast
Björn Tackenberg
@en
Björn Tackenberg
@es
Björn Tackenberg
@nl
prefLabel
Björn Tackenberg
@ast
Björn Tackenberg
@en
Björn Tackenberg
@es
Björn Tackenberg
@nl